Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Taxol commercial supply strategy

M D DeFuria1, Z Horovitz

  • 1Bristol-Myers Squibb Company, Princeton, NJ 08543-4000.

Journal of the National Cancer Institute. Monographs
|January 1, 1993
PubMed
Summary

Bristol-Myers Squibb partnered with the National Cancer Institute to commercialize Taxol, developing strategies to increase drug supply through bark extraction and alternative sourcing for cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.

The Journal of urology·1982
Same author

The effect of mitomycin C on superficial bladder cancer.

The Journal of urology·1981
Same author

Morphological effects of mitomycin C administered intravesically to normal mice and mice with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induce bladder neoplasms.

Cancer research·1980
Same author

Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.

Cancer treatment reports·1980
Same author

American experience with carminomycin.

Cancer treatment reports·1979
Same author

Amikacin, an aminoglycoside with marked activity against antibiotic-resistant clinical isolates.

The Journal of infectious diseases·1976

Area of Science:

  • Oncology
  • Pharmacology
  • Natural Product Chemistry

Background:

  • Taxol demonstrated safety and efficacy for refractory ovarian cancer, prompting the National Cancer Institute (NCI) to seek commercialization.
  • A Cooperative Research and Development Agreement was established between NCI and Bristol-Myers Squibb (BMS) for Taxol's New Drug Application (NDA) and supply.
  • BMS developed a strategic plan to ensure a robust supply chain for Taxol, crucial for clinical trials and patient access.

Purpose of the Study:

  • To outline BMS's strategic plan for expanding Taxol drug supplies.
  • To detail the evaluation of alternative sourcing options for Taxol's commercial feasibility.
  • To report on the progress made in securing sufficient Taxol quantities for treatment and research.

Main Methods:

  • Increased Taxol yield from yew bark extraction.
  • Initiated research into alternative sourcing: precursor isolation, semisynthesis, yew plantations, plant cell culture, and total synthesis.
  • Collaborated with academic and industrial investigators to address Taxol supply challenges.

Main Results:

  • Doubled Taxol yield from bark extraction within 18 months.
  • Exceeded NCI's supply requests, enabling the establishment of a cancer treatment referral center (TRC).
  • Increased NCI supplies significantly, facilitating TRC protocols for breast cancer and identifying viable alternative sources.
  • Scheduled large-scale Taxol production via precursor conversion and ensured future availability for treatment and research.

Conclusions:

  • BMS successfully implemented a multi-faceted strategy to secure and expand Taxol supply.
  • Alternative sourcing research identified commercially feasible options, diversifying production methods.
  • The strategic plan ensured adequate Taxol availability for ongoing clinical research and patient treatment needs.

Related Experiment Videos